|
ИСТИНА |
Войти в систему Регистрация |
ФНКЦ РР |
||
Prognostic role of neutrophil-to-lymphocyte ratio in patients with diffuse large B-cell lymphomaтезисы доклада
- Авторы: Kushtova Luiza B., Frantsiyants Elena M., Bandovkina Valeria A., Kozel Yuliya Yu, Dmitrieva Viktoria V., Kozyuk Olga V., Snezhko Aleksandr V., Malinin Sergey A., Chalkhakhyan Lusegen Kh, Kaminskiy Gennadiy V., Duritskiy Maksim N., Gabrichidze Petr N., Vladimirova Liubov Yu, Lysenko Irina B., Nikolaeva Nadezhda V., Kit Oleg I.
- Сборник: 2022 ASCO Annual Meeting, June 3-7, 2022; Chicago, Illinois / Journal of clinical oncology. – 2022. - Volume 40. - Issue 16. - Supplement
- Том: 40
- Тезисы
- Год издания: 2022
- Издательство: American Society of Clinical Oncology
- Местоположение издательства: United States
- Первая страница: e19560
- Последняя страница: e19560
- DOI: 10.1200/jco.2022.40.16_suppl.e19560
- Аннотация: Background: Diffuse large B-cell lymphoma (DLBCL) represents about 30-40% of all cases of non-Hodgkin lymphoma. The addition of rituximab to standard chemotherapy significantly improves survival, yet 30% of advanced-stage patients relapse. The International Prognostic Index (IPI) is used to evaluate the prognosis, but it cannot always accurately predict the outcome of therapy. The neutrophil-to-lymphocyte ratio (NLR) has recently been recognized as a prognostic factor in various types of solid tumors. The purpose of this study was to assess the prognostic value of NLR in DLBCL patients. Methods: Patients with DLBCL (n = 47) were recruited, including 31 patients in remission and 16 patients with relapsed DLBCL. All patients received 6-8 cycles of R-CHOP. Clinical parameters were studied, including IPI and complete blood count before treatment and after each chemotherapy cycle. Results: IPI predicted unfavorable outcome in 3 (18.75%) patients with relapses, and favorable outcome and high treatment efficacy in 13 (81.25%) patients. Among patients in remission, IPI predicted unfavorable outcome in 2 (6.5%) patients and favorable outcome in 29 (93.5%) patients. NLR calculation showed 100% low treatment efficacy for patients with relapses (NLR =4.1±0.51). At the same time, NLR predicted favorable outcome in 22 (70.96%) patients in remission (NLR =1.9±0.20), and relapses in 9 (29.04%) patients (NLR =4.83±0.55). 7 (22.6%) of the patients at risk developed relapses within 6-10 months after good treatment effects. Conclusions: Thus, NLR can be used as a prognostic factor in patients with DLBCL.
- Добавил в систему: Владимирова Любовь Юрьевна